Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "low dose naltrexone":

Search results

Items: 1 to 20 of 182

1.

Low-dose Naltrexone Therapy for Psoriasis.

Weinstock LB, Cottel J, Aldridge L, Egeberg A.

Int J Pharm Compd. 2020 Mar-Apr;24(2):94-96.

PMID:
32196470
2.

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.

Ma M, Wang X, Liu N, Shan F, Feng Y.

Int Immunopharmacol. 2020 Mar 11;83:106388. doi: 10.1016/j.intimp.2020.106388. [Epub ahead of print]

PMID:
32171145
3.

Low-dose naltrexone in Hailey-Hailey disease: the importance of dosing.

Acharya P, Mathur M.

Br J Dermatol. 2020 Mar 4. doi: 10.1111/bjd.19014. [Epub ahead of print]

PMID:
32133619
4.

The lowdown on low-dose naltrexone.

Shabeeb N.

Cutis. 2020 Jan;105(1):E17-E18.

PMID:
32074159
5.

Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose-Response Relationships.

Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P.

Pain Med. 2020 Feb 18. pii: pnaa001. doi: 10.1093/pm/pnaa001. [Epub ahead of print]

PMID:
32068870
6.

Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety.

Afshari R, Khadem-Rezaiyan M, Khatibi Moghadam H, Talebi M.

Toxicol Res. 2019 Nov 21;36(1):21-27. doi: 10.1007/s43188-019-00008-2. eCollection 2020 Jan.

PMID:
32042711
7.

Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome.

Zappaterra M, Shouse E, Levine RL.

Med Hypotheses. 2020 Jan 2;137:109546. doi: 10.1016/j.mehy.2019.109546. [Epub ahead of print]

PMID:
31954293
8.

Improvement of Hailey-Hailey disease with low-dose naltrexone.

Jasans-Barceló M, Curman P, Hagströmer L, Wikstrom JD, Sairafi D.

Br J Dermatol. 2020 Jan 7. doi: 10.1111/bjd.18861. [Epub ahead of print] No abstract available.

PMID:
31912486
9.

Low-dose naltrexone as a treatment for chronic fatigue syndrome.

Bolton MJ, Chapman BP, Van Marwijk H.

BMJ Case Rep. 2020 Jan 6;13(1). pii: e232502. doi: 10.1136/bcr-2019-232502.

10.

Opioid-induced hypogonadism: Pathophysiology, clinical and therapeutics review.

Antony T, Alzaharani SY, El-Ghaiesh SH.

Clin Exp Pharmacol Physiol. 2019 Dec 29. doi: 10.1111/1440-1681.13246. [Epub ahead of print] Review.

PMID:
31886562
11.

The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response.

Aboalsoud A, El-Ghaiesh SH, Abd Elmonem FF, Salem ML, Abdel Rahman MN.

Int Immunopharmacol. 2020 Jan;78:106068. doi: 10.1016/j.intimp.2019.106068. Epub 2019 Dec 10.

PMID:
31835085
12.

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.

Dalgleish AG, McLean E, Patel N, Rahman N.

Respir Med Case Rep. 2019 Nov 21;29:100971. doi: 10.1016/j.rmcr.2019.100971. eCollection 2020.

13.
14.

In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop™ for psoriasis.

Ip K, Song G, Banov D, Bassani AS, Valdez BC.

Arch Dermatol Res. 2020 Mar;312(2):145-154. doi: 10.1007/s00403-019-01981-2. Epub 2019 Oct 30.

PMID:
31667579
16.

Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial.

Badaras R, Jovaisa T, Lapinskiene I, Ivaskevicius J.

J Addict Med. 2019 Oct 11. doi: 10.1097/ADM.0000000000000560. [Epub ahead of print]

PMID:
31609865
17.
18.

Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?

Tortelly VD, De Mattos T, Fernandes LSA, Nunes BEM, Melo DF.

Dermatol Online J. 2019 Aug 15;25(8). pii: 13030/qt6j45h81f.

19.

Low-Dose Naltrexone-Induced Remission in Hailey-Hailey Disease Maintained in Remission with Topical Combination of Ketamine and Diphenhydramine.

Sonthalia S, Agrawal M, Talwar A, Goldust M.

Indian Dermatol Online J. 2019 Aug 28;10(5):567-570. doi: 10.4103/idoj.IDOJ_453_18. eCollection 2019 Sep-Oct.

20.

Hailey-Hailey disease treated successfully with naltrexone and magnesium.

Alajmi A, Jfri A, Lovett A.

JAAD Case Rep. 2019 Aug 29;5(9):760-762. doi: 10.1016/j.jdcr.2019.06.022. eCollection 2019 Sep. No abstract available.

Supplemental Content

Loading ...
Support Center